Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)

Status:

Closed to Accrual

IIIb

Phase

Adjuvant

Line of Therapy

Prevention

Disease Stage

Biomarker(s)

BRAF V600

Investigational

Product

Bruton's tyrosine kinase (Btk) inhibitor

Treatment Arms

o Experimental: Dabrafenib and trametinib combination therapy